Introduction: While options for treatment strategies for infantile hemangiomas (IH) are numerous, evidence-based information about agents, optimal dosage, adverse effects, treatment modality, pretreatment and treatment strategies remain limited. Areas covered: To evaluate side effects and adverse events of medical treatment in children with infantile hemangioma, a comprehensive review of the literature was performed to provide information for daily practice. In total 254 studies were retrieved from medical databases and comprised 10,022 patients divided into 5 different treatment groups. Information about working mechanism, side effects and adverse events of therapies used as a single agent for IH are discussed and evaluated according to information from pharmacotherapeutic databases. Randomized controlled trials have only scarcely been performed for the many therapeutic options reported for IH. Short-and long-term side effects and adverse events, have not been systematically studied. Subsequently information about the medical treatment options and pharmacotheraputic databases for therapy in children with IH are incomplete. Expert opinion: From the many therapeutic options, propranolol is the first-line approach for IH, predominantly based on clinical observation, efficacy and tolerability in the short-term. The unsolved ravels of possible short and long-term adverse events of propranolol used during early developmental stages of children need thorough review.
Introduction
Infantile hemangiomas (IH) are the most frequently observed vascular tumors in infancy, found in 4-10% of Caucasian infants. [1, 2] Several therapeutic regimens have been used to treat these benign tumors, with various outcomes. While options for treatment strategies for IH are numerous, evidence-based information about agents, optimal dosage, treatment modality, pretreatment and treatment strategies remains limited. In addition, side effects and adverse events from treatment of IH are rarely systematically reported.
The study of Léauté-Labrèze et al. published in 2008 demonstrated remarkable treatment results with the nonselective β-blocker propranolol on IH. [3] Consensus guidelines for pretreatment evaluation and monitoring of propranolol therapy for IH were proposed. [4] Side effects and adverse events reported in this guideline are bradycardia, hypotension, hypoglycemia, bronchospasm and hyperkalemia. In routine clinical practice, propranolol appears to be effective for IH, well tolerated and better than previous therapies at inducing regression. These observations, in conjunction with the immediate availability of the medication in pediatric formulations, resulted in the rapid and widespread adoption of propranolol for treatment of IH. This apparent success may also lead to a shift in treatment indications from initially functional only to cosmetic indications. Considering the potential overuse of β-blockers for uncomplicated IH and the uncertainty about short but especially longterm potential side effects and adverse events prompted us to review literature about what is already known.
We aimed to conduct a literature review of all medical therapeutic options for IH in children to provide a more safe and optimal case-based treatment approach, as well as monitoring. We specifically studied treatment mechanism of action, side effects and adverse events. General information about side effects and adverse events of these treatment strategies from pharmacotherapeutic databases was added. Our aim was to make treatment recommendations and follow-up protocols for daily practice and subsequently highlight gaps that currently exist and that should be addressed in future clinical studies.
Methods

Data source and search strategy
MEDLINE, Embase and Cochrane Library were searched in April 2014 for the search terms (treatment OR therapy) AND (hemangioma OR hemangiomas) AND (children OR infantile OR child OR juvenile OR adolescent OR neonate OR newborn OR infant) and applied data limitation, starting from January 2008 until May 2014. The reference management program RefWorks was used for the saving and de-duplication of the articles.
Selection criteria
We included studies describing medical treatment for children aged ≤18 years with IH. The selected studies had to clearly describe whether side effects or adverse events had occurred, either with detailed symptoms or no occurrence. Studies were excluded if they focused on either surgical or laser treatment or photo-or radiotherapy. Studies not written in English, Dutch, French or German were excluded, as were reviews and metaanalyses.
Study selection
Three independent researchers (FV, NE and MR) conducted the systematic search. The selection process was performed as follows:
(1) Screen resulting articles for double publications.
(2) Screen all hits on article type and language (exclude articles meeting exclusion criteria for article type or language). (3) Screen all abstracts on relevance (exclude articles beyond the scope of this research). (4) Screen full text on relevance if available (include articles reporting medical treatment for children ≤18 years of age with an IH and reporting side effects and adverse events), and if full text was not available, but all necessary information (i.e. number of patients, medicine, dose, side effects and adverse events) was listed in the abstract, the particular publication was included as well. (5) Article citation screening (add articles that met the inclusion criteria).
The researchers compared the articles remaining after this selection process, and discrepancies between reviewers were resolved by consensus.
Data extraction
Two reviewers (FV and MR) listed all included manuscripts. Number of patients, type of medication, dosage side effects and reported adverse events were registered in a database. If more than one treatment medication was used in a study, data were selected from the different treatment groups and listed as separate substudies regarding therapy and adverse effects from the included study. Available literature was evaluated for its hierarchy level of evidence (I-V).
[5]
Data analysis
The pediatric hospital pharmacist (YL) analyzed reported side effects and adverse events of the medications mentioned in the included articles by using national and international pharmacotherapeutic adult databases. [6] [7] [8] [9] [10] The pharmacist added possible serious side effects and adverse events of used medications that were not reported in the systematic literature search.
Article highlights
• Many therapeutic options are reported for infantile hemangioma (IH); currently, β-blocker therapy is the first-line treatment option for IH in children.
• The wide range of seemingly effective medical therapies for IH are merely lacking high level of evidence.
• Therapies utilized demonstrate numerous side effects and adverse events known for their effect during therapy, while long-term outcome and sequelae are unknown in IH patients.
• Pharmacotherapeutic databases are incomplete in information regarding the treatment options in children with IH.
• Current therapeutic strategies used in children during their early developmental growth need a thorough review of side effects and adverse events in the short-and long term.
This box summarizes key points contained in the article.
Results
Search results
Initially, 1969 potential eligible studies were identified in the literature search. After excluding double reports, 1287 unique articles remained. A total of 254 studies met all inclusion criteria for this review ( Figure 1 [11] ). No third-party arbitration was needed for the discrepancies between reviewers.
Patients and treatment
In these 254 studies, a total of 10,022 patients were included ( Table 1 ). All references are available as an online supplement. Six studies were case-control or retrospective comparative studies (3%), 2% were randomized controlled trials (n = 4 level I, n = 2 level II) and all other were case reports and case series from retrospective or prospective cohorts (levels III and IV).
From the included studies, subgroups of patients were made to deduct combination therapy from single-agent therapy. In total, 285 studies were revealed, with single agents in 254 studies (n = 9172 patients), covering five different treatment groups for IH (β-blockers, corticosteroids, angiotensin-converting enzyme (ACE) inhibitors, immune modulators and chemotherapy). Combination therapy was found in 31 studies (n = 850 patients). Therapies included oral, topical, intralesional and intravenous modalities. The number of patients in all studies ranged from 1 to 2013. Over 56% of all patients were treated with oral propranolol as a single agent (n = 5621). Oral prednisone was used solitary in 722 patients (7%) and topical imiquimod in 709 patients (7%). All reported side effects and adverse events were stratified per drug, therapy modality and evaluated according to adult pharmacotherapeutic databases (Tables 1 and 2 ). Some side effects and adverse events from therapy could not be found in these databases. Results from the former mentioned therapy groups used as a single agent (n = 254 studies) are discussed in more detail.
β-Blockers
Propranolol
Two randomized trials were identified that supported efficacy of propranolol, one from the search and one while performing this study. [12, 13] The nonselective lipophilic β-receptor antagonist propranolol acts by inhibition of both β-1 and β-2 adrenoreceptors. [14] It is both effective during the proliferative and the involution phase of IH growth. The mechanism of action of propranolol in IH is not yet completely understood, but it is thought to originate from several effects, like vasoconstriction, [2, 15] inhibition of angiogenesis, [16] [17] [18] [19] [20] [21] [22] [23] stimulation of apoptosis [24] and inhibition of the reninangiotensin system (RAS). [25, 26] IL: intralesional; IV: intravenous; MESNA: sodium-2-mercaptoethane sulfonate. and inertia. Occasionally (0.1-1%): diarrhea, nausea, vomiting. Rarely (0.01-0.1%): thrombocytopenia, heart block, deterioration heart failure, orthostatic hypotension, syncope, angioedema, hallucinations, psychosis, mood swings, confusion, amnesia, dizziness, paresthesia, visual impairment, dry eyes, deterioration claudicatio intermittens, bronchospasms, skin rash, deterioration psoriasis, alopecia. Extremely rare (≤0.01%): deterioration angina pectoris or myasthenia gravis, hyperhydrosis, positive antinuclear antibody serology, agranulocytosis, masking thyrotoxicosis, changes in fat metabolism, hypoglycemia, depression, headache, conjunctivitis, constipation, dry mouth, arthralgia, reduced renal function, impotence
Intralesional therapy is not specified.
Propranolol (topical)
Topical therapy is not specified.
Nadolol (oral) Bradyarrhythmia (2%), dizziness (2%), fatigue (2%), atrioventricular block (1%), cardiac dysrhythmia (1%) and heart failure (1%) a Acebutolol (oral) Arthralgia, sleep disturbances, depression, visual hallucinations, dizziness, dry eyes, bradycardia, atrioventricular conduction prolongation, heart block, heart failure, hypotension, bronchospasms in patients with bronchial and asthmatic diseases, nausea, diarrhea, pruritus, cold extremities, fatigue and positive antinuclear antibody serology Atenolol (oral) Regularly (1-10%): bradycardia, nausea, vomiting, diarrhea, tiredness and cyanotic extremities. Occasionally (0.1-1%): sleep disturbances, elevated transaminases. Rare (0.01-0.1%): thrombocytopenia, leucopenia, Raynaud's phenomena, hallucinations, psychosis, depression, confusion, dizziness, paresthesia, hypotension, aggravated heart failure, slow atrioventricular node conduction or increase in existing atrioventricular block, hepatotoxicity and bronchospasms, deterioration claudication intermittens, heart failure, headache, visual impairment, dry eyes, bronchospasms, dry mouth, hepatotoxicity, alopecia, impotence, thrombocytopenia. Extremely rare (≤0.01%):
positive antinuclear antibody serology, urticaria, exanthema, angioedema, masking symptoms of hypoglycemia and thyrotoxicosis Timolol (topical) Occasionally (0.1-1%): asthenia, dizziness, depression, headache, respiratory problems, nausea, dyspepsia, bradycardia and syncope. Rarely (0.01-0.1%): hypotension, palpitation, insomnia, nightmares, amnesia, deterioration myasthenia gravis, tinnitus, dry mouth, diarrhea, decompensatio cordis, Raynaud's phenomena, edema, cough, alopecia, hypoglycemia, urticaria, chest pain, skin rash, arrhythmia, heart block, cardiac arrest, positive antinuclear antibody serology, cerebral ischemia and heart failure* central nervous system (CNS) symptoms. Intralesional propranolol studies (n = 4) showed symptoms due to pain at the injection site and redness of the skin, while topical propranolol studies (n = 5) revealed no adverse effects.
Atenolol
Itinteang et al. suggested that propranolol acts via the RAS in regulating accelerated involution of proliferating IH by decreasing renin production in the kidneys. [25] As the kidneys predominantly express β-1 receptors, the renin-angiotensin-aldosterone system (RAAS) is most likely one of the missing links in understanding the working mechanism of both β-blockers and ACE inhibitors in the treatment of IH. [27] Atenolol is a hydrophilic β-blocker, acting on β-1 receptors with a proven efficacy in the treatment of IH. [28, 29] Another explanation for the effect of atenolol could be the limited β-2-blocking potential of atenolol. [30] In the studies used in this overview, the reported side effects and adverse events noted were hypotension, sleep disturbance, constipation, diarrhea, cold extremities and vomiting.
Timolol
Timolol is a nonselective lipophilic β-blocker that is comparable to propranolol in mechanism of action. While timolol is available as a liquid gel, it can be topically administered to superficial IH as can propranolol cream. [31] Topical application reveals limited systemic absorption, and therefore, systemic side effects and adverse events are uncommon. However, Weibel et al. showed that 83% of children treated with topical timolol had urinary timolol excretion, suggestive of systemic uptake. [32] One study reported sleeping disturbance in one patient, which is also suggestive of systemic side effects of topical administration. [33] One randomized trial with 41 patients with superficial IH revealed effectiveness of timolol without significant differences in heart rate or blood pressure measurements compared to placebo. [34] 
Corticosteroids
Although corticosteroids have been the basis of treatment in IHs for half a century, little is known about the exact working mechanism in IH. It is suggested that dexamethasone suppresses vasculogenesis of hemangioma-derived stem cells in vitro and corticosteroids diminish secretion of vascular endothelial growth factor (VEGF)-A from these stem cells in vitro. [35] A decrease in VEGF-A can sufficiently suppress vasculogenesis of hemangioma-derived stem cells in vivo. Corticosteroids are not able to suppress VEGF-A if it is from hemangioma-derived endothelial cells from human umbilical cords. [35] VEGF-A was detected in the proliferative phase of IH, but not in the involution phase. This might explain why corticosteroids are most effective during the proliferative phase of the IH. Corticosteroids can be used systemically, intralesional and as a topical treatment for IH. One randomized trial is known for the effectiveness of corticosteroids in IH in comparison to propranolol versus both. [36] The conclusion was that prednisolone was associated with a higher number of complications, thereby decreasing patient compliance. Propranolol showed a consistent, rapid therapeutic effect compared to prednisolone. A combination of the two had a comparable but not superior efficacy than propranolol alone. Another randomized controlled trial by Baumann et al. revealed a similar efficacy of both drugs. [37] Prednisolone showed a faster response rate while propranolol was better tolerated with significantly fewer severe short-term adverse events. In this review, side effects and adverse events of systemically used corticosteroids were seen in 20 studies with a total of 722 patients and included symptoms of metabolic, cardiovascular, endocrine, gastrointestinal, infectious, respiratory, CNS and dermatological origin. Intralesional corticosteroid therapy showed local skin symptoms varying from skin atrophy to necrosis, but it also revealed systemic side effects and adverse events (cushingoid appearance, failure to thrive, adrenal insufficiency with transient reductions of weight and linear growth, infection, hypertension).
ACE-inhibitors
The RAAS is involved in the proliferative phase of IH growth. This is supported by the observation of the negative action of propranolol on renin or the suppression of ACE by ACE-inhibitors like captopril. Both actions result in diminished production of angiotensin 2 and a subsequent regression of IH. [25] Sinaiko et al. found elevated levels of renin in children treated with ACE-inhibitors, suggesting that suppression of renin by β-blockers in addition to ACEinhibition creates an even larger effect on IH regression. [25, 38] No further evidence in literature could be found for this therapy. Adverse effects in this overview came from one study with eight patients showing a transient mild creatinine elevation in the first week of treatment in one of the patients. [27] 3.6. Immune modulators
Imiquimod (topical)
Imiquimod is known to influence the immune system by induction of cytokine synthesis and thereby stimulating secretion of cytokines from macrophages, monocytes and keratinocytes in the epidermis. These cytokines, interferon (IFN), tumor necrosis factor − and interleukins (ILs) lead to a reduction of pro-angiogenic factors, cell death in endothelial cells and to a decreased tumor invasion and cell motility. [39] Furthermore, IL-12 is known for its inhibition of the angiogenesis in vivo and tube forming of endothelial cells in vitro. [40] Studies in mice revealed that imiquimod could result in a decreased activity of matrix metalloproteinase-9.
[39] Therefore, the mechanism of action of imiquimod is ascribed to a cascade that results in the synthesis of cytokines that inhibit growth of IH.
[41] We identified no evidence-based trials in IH. We included 10 papers with a total of 709 IH patients treated with imiquimod. Adverse effects reported were both local skin reactions and systemic symptoms of fever and gastrointestinal complaints. [43] In 58 patients using IFN-− injections for IH, several adverse effects were reported; gastrointestinal, metabolic disturbances but also general symptoms such as fever, fatigue, hair loss and flu-like symptoms.
Sirolimus
Mammalian target of rapamycin (mTOR) acts as a master switch for numerous cellular processes including angiogenesis and cell growth. [44] Sirolimus is an mTOR inhibitor and could therefore be beneficial in the treatment of vascular anomalies. [45] In a case report with only one patient, several side effects and adverse events occurred (hypertriglyceridemia, febrile neutropenia and mild mucositis). [46] 3.7. Chemotherapy
Bleomycin (intralesional)
Bleomycin is a cytotoxic agent that is able to degrade deoxyribonucleic acid (DNA), which results in an inhibition of cell replication, cell growth and DNA synthesis in tumor biology. It is used for intralesional treatment in IH. This sclerosing agent acts on vascular endothelium by induction of cell injury and disperse endothelial cells, leading to occlusion of blood vessels. Overall, it stimulates apoptosis of rapidly dividing cells, as is seen in proliferating IH. [47] The literature is limited for retrospective and prospective case studies only. In three studies of bleomycin-only intralesional therapy for IH, side effects and adverse events in 123 patients consisted of local symptoms at the injection site, but also systemic gastrointestinal complaints.
Vincristine
The vinca-alkaloid vincristine is known for its systemic chemotherapeutic action in malignancies. It negatively influences vascular and endothelial cell growth, inducing apoptosis and is furthermore able to stop mitosis by inhibiting the formation of microtubules. [48] Evidence-based trials with vincristine in IH are not available. Vincristine was used in two reports with eight patients of IH and reported side effects were due to infectious and peripheral nervous system origin.
Cyclophosphamide
Cyclophosphamide is an alkylating agent affecting DNA and the cell cycle process. It is furthermore known for its immunosuppressive effect on B and T cells. [6] One case with diffuse neonatal hemangiomatosis was treated with cyclophosphamide and suffered from fever, sepsis, catheter infection and hypertension. [49] 
Discussion
A proper diagnosis of IH should be obtained before starting any therapy. Although this statement is beyond the scope of this report, it is especially true for initiating systemic therapy for IH with potential side effects and adverse events. This review focuses specifically on reported side effects and adverse events of any medical treatment strategy in IH. This comprehensive overview of literature was performed by stratification of all reported side effects and adverse events per drug and treatment modality instead of by frequencies in patients. The outcome demonstrates that IH are treated with a wide range of medications. In total, 10,022 patients treated in five different single-treatment medication groups for IH were included. Randomized controlled trails have only scarcely been performed for any of the reported treatment strategies. Short-and longterm side effects and adverse events are even less well studied. Pharmacotherapeutic databases are incomplete in information regarding the treatment options in children with IH. Corticosteroids are well known for their adverse effects and are therefore no longer considered a first-line treatment in pediatric IH. β-Blockers have become the first-line treatment modality for complicated hemangiomas. They appear to be more successful than corticosteroids, also beyond the proliferative phase, [50] while they have less side effects, although short and especially long-term adverse events are not systematically studied. The lipophilic nonselective character of propranolol causes cardiovascular, respiratory and CNS adverse effects. While the hydrophilic and more selective β-blocker atenolol is a promising alternative, its efficacy, side effects and adverse events spectrum have not been studied as extensively yet. [27] [28] [29] [51] [52] [53] Topical β-blocker treatment possibly has less systemic adverse effects but it seems to be effective only in superficial IH. [31] ACE-inhibition seems to be a good alternative by its action mechanism, although literature is very limited and renal adverse effects at young age can be harmful. [27] Chemotherapy and immune modulator therapies have also been studied but are known for serious side effects and are currently replaced by less harmful strategies that appear to have at least similar effectiveness. Tables 3 and 4 show effective therapies in children with IH, according to literature with dosage, pretreatment and treatment strategies. In addition, they depict common, unusual, serious and harmless side effects and adverse events. This overview might be helpful for the treating physician making a deliberate individualized or case-based choice for any patient with complicated IH according to current knowledge at any point during treatment. Moreover, we hope this review will be an impetus for further research since especially long-term side effects in this young patient population are unknown. While Table 3 focuses on first-and second-line therapy, Table 4 shows therapies that should only be used in case of severe complicated IH not responding to first-or second-line therapy. After consulting a vascular expert team, first-line therapy can be used in general practice, according to a standardized protocol. Second-and third-line therapy for IH though should be indicated and coordinated by a multidisciplinary team with expert knowledge on vascular abnormalities in children. Systemic immune modulator and chemotherapy medication are currently only indicated in severe complicated IH not responding to any other treatment and should exclusively be under team expert auspices. In the absence of evidence-based literature, it is hard to judge the most efficacious and safest therapy from the reviewed options.
The results of the conducted review have limitations by the low levels of evidence of included studies, small sample size for some therapy modalities, lack of available data on especially systematically studied side effects and adverse events and absence of longitudinal follow-up studies. Current review shows the side effects and adverse events listed by therapy without any denominator, which is a limitation that might leave the clinician with many uncertainties. Possibly also side effects and adverse events are underreported by this conducted review analysis. Furthermore, propranolol is offered to a much larger population than corticosteroids ever were, which is reflected in this overview and accounts for an unsolved bias. Limitations in the use of pharmacotherapeutic databases were due to lack of information about specific treatment options for IH and the fact that derived information is from treated adults mostly for other indications. Several of the observed side effects and adverse events in the pediatric IH population are not reported in adult pharmacotherapeutic databases. This shows that the available databases currently are incomplete and should be updated. This is of importance to all professionals participating in the care of IH patients.
In conclusion, there is a wide range of seemingly effective medical therapies for IH, although high level of evidence is still limited. Therapies utilized demonstrate numerous side effects and adverse events merely known for their effect during therapy, while long-term outcome and sequelae are unknown in these patients. In order to guide the clinician to judge the most efficacious and safest therapy for an individual patient, the list of therapeutic options for IH in children was reviewed. To date, first-line treatment in patients with IH is β-blocker therapy. This approach is based on clinical observation, efficacy and tolerability of propranolol, especially in the short term. Considering potential overuse of β-blockers for uncomplicated IH and the uncertainty about long-term potential side effects and adverse events still makes critically weighing the treatment indication and more comprehensive review studies of great importance.
Expert opinion
The first-line approach with propranolol for IH seems to be predominantly based on clinical observation, efficacy and tolerability in the short term. Only 7 years after the first report of Léauté-Labrèze et al. [3] , little is known about the long-term outcome and safety. The recently performed randomized controlled trial by Léauté-Labrèze [13] showed that propranolol was effective at a dose of 3 mg/kg/day for 6 months for IH. It revealed a safety assessment by analysis of adverse events, which according to the authors included neurodevelopment revealed no notable differences between the propranolol treatment arms and the placebo group. Unfortunately, the report does not specify in detail what variables were studied with regard to neurodevelopment and follow-up time was relatively short. The qualification of propranolol as a safe treatment strategy for IH in pediatric patients should therefore be interpreted with caution. To date, detailed assessment of cardiovascular, gross motor and neurocognitive development has not yet been published in IH patients treated with propranolol. Subsequently, short-and long-term development outcome of treated infants with IH is unknown. Only one very recent study by Moyakine et al. showed that in 103 patients with IH treated with propanolol no evidence of psychomotor developmental delay was found. [54] It remains possible though, the authors concluded, that propranolol treatment causes subtle adverse effects, which cannot be traced with tools such as the van Wiechen scheme. And as such, they suggest that future prospective studies using universal screening tools such as the Parents Evaluation of Developmental Status, the Ages and Stages Questionnaire or more advanced neuropsychological tests are needed to support their findings. Kwon et al. reported on the analyses of infants treated with propranolol for various indications, including IH. [55] It demonstrated that no serious adverse events resulted in hospitalization and supported the perceived safety profile of propranolol. Results also implied that serious adverse events might be delayed and thus not detected during initiation of the drug treatment. It is unknown whether young infants with IH and a normotensive cardiovascular system have a different complication risk of propranolol therapy compared to those infants treated with propranolol for cardiac indications. Data on long-term outcome of patients treated with β-blockers for other indications than IH, for example, patients with arrhythmic diseases, are lacking in literature. Another concern is the observation by Gonski, who noted that 4 of 84 IH patients with oral propranolol for IH demonstrated a delay in unassisted walking. [56] In support of this, Langley summarizes many associated CNS effects of propranolol, including a meta-analysis of Lonergan, showing propranolol treatment negatively influences recall of emotional material. [57, 58] We endorse the concern raised by Langley about the unknown significance of CNS effects resulting from propranolol use in IH patients during early developmental stages and/or for prolonged periods of therapy. This concern is confirmed in adult literature revealing a reduction in subsequent memory for both new and previously learned emotional material and an impairment of mood and sleep quality by propranolol. [58] [59] [60] These findings suggest that this current therapeutic strategy needs to be updated with a thorough review of side effects and adverse events in short and especially long term to judge β-blocker therapy in its safety. The possibility to exchange the long-term sequelae of high-dose prednisone into acceptable short-term adverse events of propranolol seemed more important than the unsolved ravels of possible long-term adverse events of propranolol. It is imperative that these unsolved ravels need thorough review during early developmental stages and especially in long-term follow-up studies to judge safety of propranolol. Moreover, in the absence of this information, we are in favor of withholding propranolol therapy for pure cosmetic indications.
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